Register Now: Does Your Pharmaceutical WMS Grow with You?
News|Articles|February 28, 2025

Pharma Pulse 2/28/25: Delivering Personalized Experiences at Scale, Combat Counterfeit Medications & more

The latest news for pharma industry insiders.

Delivering Personalized Experiences at Scale: A Fresh Look at Customer Centricity

Customer centricity. An overused buzzword in the life sciences industry. Yet an important goal. In an era of eroding rep access, fragmented channels and growing complexity in treatment decisions, building a customer-centric commercial operation is more difficult than ever.

Combat Counterfeit Medications

When educating patients, emphasize the importance of buying drugs from only licensed pharmacies.

HHS Lays Off Lawyers Who Were Defending Medicare Drug Price Cuts

At least three government lawyers working on defending a major Biden-era drug pricing law were laid off in mass cuts across the agency this month, according to a source familiar with the terminations.

HighByte Launches API Builder for Industrial Data

HighByte announced the release of HighByte Intelligence Hub version 4.1 with Callable Pipelines. Callable Pipelines, together with the REST Data Server, functionally serve as an “Industrial Data API Builder” that allows users to build custom API endpoints to interact with industrial data. In addition to Pipelines enhancements, version 4.1 delivers native integration with Aspen InfoPlus.21, support for the new Amazon S3 Tables service, granular audit logging for regulated industries, and seamless event capture from file-based data sources.

Cencora | Pharma solutions on LinkedIn

Listen in as Jenna Dale, MBA, Director of Client Relations, shares more on the challenges associated with meeting the FDA’s 2025 cell and gene therapy forecasted approval goal, emphasizes the progress being made, and offers advice for all stakeholders on how pharma can collectively work together to reach that goal.
#CGT #cellandgenetherapy

Have news you want us to share in Pharma Pulse? Reach out to Editor Miranda Schmalfuhs


Related to this article

CVS Pharmacy Sign at Storefront Entrance | © Mark Roger Bailey - stock.adobe.com 557616813
In this week’s Pharma Pulse, CVS Health plans to separate into two public companies, Bayer weighs what MFN pricing could mean for its launch strategies and an ACTO survey finds most life sciences leaders see no clear industry standard for responsible AI.